Background
Nakajo-Nishimura syndrome/chronic, interferon genes-associated vasculopathy, AGS, lipodystrophy, neutrophilic dermatosis
LIPODYSTROPHY, NEUTROPHILIC DERMATOSIS
This study evaluated the efficacy and safety of baricitinib (Janus kinase-1/2 inhibitor), in adult and pediatric Japanese patients with Nakajo-Nishimura syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS/CANDLE), stimulator of interferon genes-associated vasculopathy with onset during infancy (SAVI), or Aicardi-Goutières syndrome (AGS).